Ashton Kutcher's Battle With Vasculitis
Title: Ashton Kutcher ' s Battle With VasculitisCategory: Health NewsCreated: 8/9/2022 12:00:00 AMLast Editorial Review: 8/9/2022 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - August 9, 2022 Category: Cardiology Source Type: news
Ashton Kutcher says he battled the debilitating disease 'vasculitis.' Here's what it is
Ashton Kutcher revealed Monday he has battled a serious autoimmune condition called vasculitis that affected his vision, hearing and gait. (Source: CNN.com - Health)
Source: CNN.com - Health - August 8, 2022 Category: Consumer Health News Source Type: news
Ashton Kutcher says rare disease left him unable to see, hear, walk
Kutcher speaks about his experience with vasculitis on a coming episode of "Running Wild with Bear Grylls: The Challenge." #ashtonkutcher (Source: Reuters: Health)
Source: Reuters: Health - August 8, 2022 Category: Consumer Health News Source Type: news
Ashton Kutcher Likely Had an ‘Extremely Severe’ Form of Vasculitis, Doctor Explains
A drug often used to treat vasculitis — and also used to terminate pregnancies — may become more difficult to access in a post-Roe v. Wade world, experts say #postroevwade #ashtonkutcher (Source: Reuters: Health)
Source: Reuters: Health - August 8, 2022 Category: Consumer Health News Source Type: news
Ashton Kutcher says he battled the debilitating disease'vasculitis.' Here's what it is
Ashton Kutcher revealed Monday he has battled a serious autoimmune condition called vasculitis that affected his vision, hearing and gait. #ashtonkutcher (Source: Reuters: Health)
Source: Reuters: Health - August 8, 2022 Category: Consumer Health News Source Type: news
Ashton Kutcher and Mila Kunis Enjoy Santa Barbara Beach Day Amid News of His Health Battle
Two days before Ashton Kutcher publicly shared that he battled a rare form of vasculitis, the actor caught some rays on a Santa Barbara beach with his wife Mila Kunis. #santabarbarabeachday #milakunis #ashtonkutcher #santabarbara #hishealthbattletwo (Source: Reuters: Health)
Source: Reuters: Health - August 8, 2022 Category: Consumer Health News Source Type: news
Ashton Kutcher ‘Lucky to Be Alive’ After ‘Super Rare’ Disease Left Him Unable to See or Hear: ‘It Took a Year’ to Recover
Ashton Kutcher revealed on a new episode of National Geographic’s “Running Wild With Bear Grylls: The Challenge” that he was diagnosed with a rare form of vasculitis nearly two years ag… #luckytobealive #recoverashtonkutcher #nationalgeographic (Source: Reuters: Health)
Source: Reuters: Health - August 8, 2022 Category: Consumer Health News Source Type: news
Ashton Kutcher Details His Battle With Rare Autoimmune Disorder - E! Online
For the first time, Ashton Kutcher opened up about his battle with a "super rare form of vasculitis,” which he said “knocked out” his vision, hearing and equilibrium. #ashtonkutcher #eonline (Source: Reuters: Health)
Source: Reuters: Health - August 8, 2022 Category: Consumer Health News Source Type: news
What Are Causes of Childhood Interstital Lung Disease?
Discussion
Interstitial lung disease in children (chILD) is less understood than adult interstitial lung disease (ILD) and is rare. Prevalence is ~ 0.13 to 16.2 per 100,000 children under age 17 years. chILD is an general term for respiratory disorders that are heterogeneous, chronic and impair lung function. While some define diffuse parenchymal lung disease (DPLD) separately, the term ILD usually encompases DPLD. chILD has variable definitions and is “usually diagnosed if three of the following features are present:
1) respiratory symptoms (cough, rapid and/or difficult breathing, and exercise intolerance),
2) res...
Source: PediatricEducation.org - August 1, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche achieves good results in the first six months of 2022
Basel, 21 July 2022Group sales up 5%1 at constant exchange rates (CER) and 5% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for new medicines to treat severe diseases; as expected, the impact of biosimilars slows down furtherDiagnostics Divisionsales grow 11%; ongoing strong base business; demand for COVID-19 tests is expected to decline in the second half of the yearIFRSnet income increases by 12% (12% in Swiss francs), whilecore earnings per share are up 11%Highlights in the second quarter:EU approvals ofPolivy (first-line treatment for aggressive form of blood cancer),Lunsumio (follic...
Source: Roche Media News - July 21, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche achieves good results in the first six months of 2022
Group sales up 5%1 at constant exchange rates (CER) and 5% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for new medicines to treat severe diseases; as expected, the impact of biosimilars slows down furtherDiagnostics Divisionsales grow 11%; ongoing strong base business; demand for COVID-19 tests is expected to decline in the second half of the yearIFRSnet income increases by 12% (12% in Swiss francs), whilecore earnings per share are up 11%Highlights in the second quarter:EU approvals ofPolivy (first-line treatment for aggressive form of blood cancer),Lunsumio (follicular lymphoma) andT...
Source: Roche Investor Update - July 21, 2022 Category: Pharmaceuticals Source Type: news
New two-year data confirm Roche ’s Vabysmo improves vision with fewer treatments for people with neovascular age-related macular degeneration
In the TENAYA and LUCERNE studies, more than 60% ofVabysmo patientscould be treated every four months at two years. This represents an increase from 45% at year onePatients treated withVabysmo received a median number of 10 injections over the two years versus 15 injections for those treated withaflibercept, potentially decreasing the number of injectionsNo new safety signals were identified andVabysmo continued to be well tolerated, with afavourable benefit-risk profileBasel, 14 July 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new two-year data from the TENAYA and LUCERNE studies that reinforce the long-term...
Source: Roche Investor Update - July 14, 2022 Category: Pharmaceuticals Source Type: news
New two-year data confirm Roche ’s Vabysmo improves vision with fewer treatments for people with neovascular age-related macular degeneration
In the TENAYA and LUCERNE studies, more than 60% ofVabysmo patientscould be treated every four months at two years. This represents an increase from 45% at year onePatients treated withVabysmo received a median number of 10 injections over the two years versus 15 injections for those treated withaflibercept, potentially decreasing the number of injectionsNo new safety signals were identified andVabysmo continued to be well tolerated, with afavourable benefit-risk profileBasel, 14 July 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new two-year data from the TENAYA and LUCERNE studies that reinforce the long-term...
Source: Roche Media News - July 14, 2022 Category: Pharmaceuticals Source Type: news
Alemtuzumab for Refractory Primary Systemic Vasculitis Alemtuzumab for Refractory Primary Systemic Vasculitis
Alemtuzumab may provide another safe and effective treatment option for primary systemic vasculitis patients who failed to respond to other therapies.Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 21, 2022 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
FDA Approves Brolucizumab for Diabetic Macular Edema FDA Approves Brolucizumab for Diabetic Macular Edema
Brolucizumab wins approval for diabetic macular edema but with a warning of retinal vasculitis and retinal vascular occlusion.FDA Approvals (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - June 8, 2022 Category: Endocrinology Tags: Ophthalmology News Alert Source Type: news
